Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on archived material of the primary tumor. However, this status may change over the course of treatment or disease progression. The aim of this study was to assess the dynamics of HER2 status in esophageal adenocarcinoma (EAC) in patients with resectable and recurrent disease, and to determine the associations of these changes with clinical outcome. Discordance, defined as any change in HER2 status between matched biopsy and post-neoadjuvant chemoradi...
Background: HER2 and topoisomerase 2 alpha (TOP2A) genomic status was previously reported to predict...
PURPOSE Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth fac...
PURPOSE Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth fac...
Trastuzumab combined with chemotherapy is standard of care for HER2 positive advanced gastro-esophag...
Background: Patients with HER2 positive adenocarcinoma of the esophagus or stomach are eligible for ...
Trastuzumab has recently been introduced as a treatment for HER2-positive metastatic and/or unresect...
Background Addition of trastuzumab to first-line palliative chemotherapy in gastroesophageal cancer ...
PurposeHER2 expression has been reported to be discordant between primary tumor and metastatic tissu...
Introduction: emerging literature data have shown a change of HER2 expression from primary tumors to...
Background: Addition of trastuzumab to first-line palliative chemotherapy in gastroesophageal cancer...
Background: The assessment of human epidermal growth factor receptor 2 (HER2) gene amplification is ...
In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) sta...
HER2 (human epidermal growth factor receptor-2) assessment in histological samples of gastric cancer...
We analysed trends over time in palliative first-line chemotherapy in patients with locally advanced...
Anti-HER2 therapies have dramatically improved the prognosis of human epidermal growth factor recept...
Background: HER2 and topoisomerase 2 alpha (TOP2A) genomic status was previously reported to predict...
PURPOSE Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth fac...
PURPOSE Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth fac...
Trastuzumab combined with chemotherapy is standard of care for HER2 positive advanced gastro-esophag...
Background: Patients with HER2 positive adenocarcinoma of the esophagus or stomach are eligible for ...
Trastuzumab has recently been introduced as a treatment for HER2-positive metastatic and/or unresect...
Background Addition of trastuzumab to first-line palliative chemotherapy in gastroesophageal cancer ...
PurposeHER2 expression has been reported to be discordant between primary tumor and metastatic tissu...
Introduction: emerging literature data have shown a change of HER2 expression from primary tumors to...
Background: Addition of trastuzumab to first-line palliative chemotherapy in gastroesophageal cancer...
Background: The assessment of human epidermal growth factor receptor 2 (HER2) gene amplification is ...
In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) sta...
HER2 (human epidermal growth factor receptor-2) assessment in histological samples of gastric cancer...
We analysed trends over time in palliative first-line chemotherapy in patients with locally advanced...
Anti-HER2 therapies have dramatically improved the prognosis of human epidermal growth factor recept...
Background: HER2 and topoisomerase 2 alpha (TOP2A) genomic status was previously reported to predict...
PURPOSE Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth fac...
PURPOSE Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth fac...